Lokon Pharma is advancing its LOAd (Locally Optimised Adenovirus) platform, a novel approach to cancer immunotherapy that utilizes gene-engineered vectors to modulate the tumor microenvironment (TME) and stimulate systemic anti-tumor immunity. The LOAd platform encompasses a range of vectors armed with different immunostimulatory genes, each designed to address specific aspects of immune suppression within the TME.
The company is currently focused on evaluating the mechanisms-of-action (MOA) and proof-of-concept (POC) of various LOAd vectors in preclinical and clinical studies. These studies aim to elucidate how LOAd vectors can reprogram the TME to overcome immune resistance and promote durable anti-tumor responses.
Clinical Trial Programs
Lokon Pharma is actively recruiting patients for several clinical trials evaluating LOAd vectors in different solid tumor types. The LOKON001 and LOKON003 trials are open to patients with pancreatic cancer or melanoma in the US, while the LOKON002 and LOKON003 trials are enrolling patients with pancreatic cancer, melanoma, or ovarian cancer in Sweden.
These trials are designed to assess the safety, tolerability, and preliminary efficacy of LOAd vectors administered directly into tumors. Key endpoints include assessment of TME modulation, immune cell infiltration, and clinical response. Patients interested in participating in these trials are encouraged to discuss their eligibility with their treating physician.
